Sugammadex Administration in Pregnant Women and in Women of Reproductive Potential: A Narrative Review. Issue 4 (December 2020)

• Record Type: Journal Article
• Authors: Richardson, M.G.; Raymond, B.L.
• Is Part Of: Obstetric anesthesia digest. Volume 40:Issue 4(2020)
• Publication Date: 2020-12
• Subjects: Pharmacology -- Maternal Mortality and Morbidity; Anesthesia in obstetrics -- Periodicals; Anesthesia in obstetrics -- Abstracts -- Periodicals; 617.968205
• DOI: 10.1097/01.aoa.0000719488.32191.77
• Languages: English
• ISSNs: 0275-665X

Abstract

Abstract : ( Anesth Analg . 2020;130:1628–1637) The approval in 2008 for clinical use of the drug sugammadex has led to its rapid replacement of neostigmine to reverse rocuronium and vecuronium's neuromuscular blocking (NMB) effects. While its cost is higher, sugammadex's effectiveness and relative lack of side effects render it the superior choice compared with neostigmine. However, while thorough studies exist for this medication, few of them apply to its use in pregnancy and for women of childbearing potential. Thus, the author's aim of this narrative was to review the use of sugammadex in pregnant women undergoing nonobstetric surgery, women potentially capable of childbearing using hormone-based contraception, lactating women, and parturients undergoing cesarean delivery (CD), as well as to provide up-to-date evidence in these cases.